RHIZEN-PHARMACEUTICALS
Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company, today announced the approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to study its oral DHODH inhibitor for SARS-CoV-2 infection. The company announced that initial study shall evaluate single ascending doses of RP7214 in healthy volunteers and that dosing is expected to commence in early December 2020. The company also announces positive feedback from the FDA during its pre-IND discussion on its plans to follow-up this study with a multiple-ascending dose study in Covid-19 patients.
Dihydroorotate dehydrogenase (DHOHD) is a key enzyme involved in pyrimidine biosynthesis in the cell. RP7214 is potentially a best-in-class selective DHODH inhibitor that has shown potent inhibition of Covid-19 viral replication. RP7214 has also been studied extensively across multiple inflammation models where it has demonstrated excellent anti-inflammatory activity. Further, the IND-enabling preclinical studies have shown RP7214 to be orally available, safe and tolerable with predictable dose-linear pharmacokinetics. The host-based mechanism of RP7214 could allow complementary combinations with direct acting anti-viral drugs, while the broad anti-inflammatory action could potentially mitigate the cytokine mediated inflammatory symptoms typically seen in SARS-CoV-2 & other viral infections.
Swaroop Vakkalanka, President & CEO of Rhizen Pharmaceuticals said “There is an exceptional need for oral antiviral drugs that are suitable for Covid-19 treatment across all hospital and out-patient settings. We are pleased to advance RP7214 into a Phase 1 clinical trial for the treatment of Covid-19 under a US FDA IND. RP7214 has a unique preclinical profile, high oral bioavailability, robust anti-viral potency and broad anti-inflammatory role, that we expect will translate in the clinic and support its eventual development as a potential treatment for Covid-19 ”.
About Rhizen Pharmaceuticals S.A.:
Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel onco-therapeutics. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland. For additional information, please visit www.rhizen.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201201005815/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WeWork Companies LLC Commends Franchisee WeWork India on IPO and Public Listing14.10.2025 16:00:00 CEST | Press release
Milestone underscores strength of the WeWork global brand and WeWork India’s position as the country’s leading flexible office space provider WeWork Companies LLC (WeWork), the privately held parent company of its franchisee WeWork India Management Limited (“WeWork India”), applauds and fully supports the launch of their IPO and listing on the National Stock Exchange of India. The entities have enjoyed a long and positive partnership since WeWork India’s founding in 2017, during which time it has grown to become the top flexible office space provider in the country. “WeWork India is shaping the future of work in India,” said John Santora, Chief Executive Officer of WeWork. “The listing marks an important moment for the country’s flexible workspace sector, underscoring both market confidence and growing demand for dynamic office solutions in the region. We have been a proud partner of WeWork India and have witnessed their rise as the clear leader in the space in which they operate.” “Ov
LevelBlue to Acquire Cybereason, Expanding Global Leadership in Managed Detection and Response, XDR, Incident Response, and Threat Intelligence14.10.2025 16:00:00 CEST | Press release
Acquisition Strengthens LevelBlue’s Position as the World’s Largest Pure-Play MSSP; Adds Investment from SoftBank Corp., SoftBank Vision Fund 2, and Liberty Strategic Capital LevelBlue, the world’s largest pure-play provider of managed security services, today announced it has signed a definitive agreement to acquire Cybereason, a leading cybersecurity firm known for its advanced Extended Detection and Response (XDR) platform, elite threat intelligence team, and digital forensics and incident response (DFIR) capabilities. For clients and strategic partners, the acquisition delivers immediate value with stronger threat detection, faster response, and broader global coverage, all from a single, unified security partner. By combining LevelBlue’s AI-powered capabilities and industry-leading MDR offerings with Cybereason’s deep expertise, organizations can better address today’s complex cyber challenges while reducing operational complexity and risk. “The addition of Cybereason is a strateg
Interactive Brokers Launches Enhanced Version of IBKR Desktop with One-Click, Instant Order Placement14.10.2025 16:00:00 CEST | Press release
Active traders benefit from market intelligence, product discovery, and execution tools in a modern, scalable interface Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced the release of Version 1.2 of IBKR Desktop, a next-generation trading platform that balances simplicity with advanced functionality. The improved version offers new features and tools, including one-click, instant order transmission which is a highly requested and sought-after feature for Interactive Brokers’ active and sophisticated traders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251014910329/en/ Interactive Brokers Launches Enhanced Versions of IBKR Desktop with One-Click, Instant Order Placement. With IBKR Desktop, clients can trade products from over 160 global exchanges, including stocks, options, futures, currencies, bonds, and funds, from a single unified platform, and access popular and exclusive tools
Bobbi Brown Cosmetics Announces Sara Foster as Global Brand Ambassador14.10.2025 15:32:00 CEST | Press release
Partnership celebrates authenticity, confidence, and the beauty of being effortlessly put-together. Bobbi Brown Cosmetics is proud to announce actress, entrepreneur, and podcast host Sara Foster as its newest Global Ambassador, marking the beginning of a long-term partnership that will spotlight the brand’s “Effortlessly Put-Together” campaign and celebrate its timeless philosophy of confidence through simplicity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251014443911/en/ Known for her sharp humor, relatable candor, and modern take on beauty, Sara has become a voice for women seeking balance amid busy, multifaceted lives. As co-founder of the fashion label Favorite Daughter, co-host of the hit podcast The World’s First Podcast, executive producer of Netflix’s Nobody Wants This, and a devoted mother, she embodies the Bobbi Brown ethos: real beauty that works for real life. “Bobbi Brown has always celebrated real women an
Gurobi Signs Partnership Agreement with GRID Inc.14.10.2025 15:00:00 CEST | Press release
Strategic collaboration to advance mathematical optimization technology in energy and social infrastructure. Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced a new partnership with GRID Inc., an AI optimization company specializing in infrastructure solutions. GRID is a rapidly growing company that develops AI optimization solutions for the infrastructure sector. After transitioning from the renewable energy business to AI, the company was selected for NEDO's startup support program and successfully listed on the Tokyo Stock Exchange Growth Market in 2023. GRID leverages digital twins and deep learning to predict and optimize complex planning operations—including power generation facility scheduling and transmission network routing—contributing to infrastructure efficiency and decarbonization. The partnership combines GRID's AI and digital twin expertise with Gurobi's advanced solver technology to meet growing optimization demands in the energy
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom